Can Eucrisa (crisaborole) be used on facial atopic dermatitis?
Eucrisa (crisaborole) is approved for mild-to-moderate atopic dermatitis (eczema) in people age 2 years and older. Because it’s a topical non-steroid cream, some clinicians use it on body areas that are prone to flares, including sensitive areas. However, facial skin is more easily irritated, so you should only use it on the face if your prescriber has told you to, and take extra care to avoid the eyes and eyelids.
What precautions matter if you apply it to the face?
For facial use, the key risk is irritation, especially around the eyes. Avoid getting Eucrisa in or near the eyes, on the eyelids, or on the lips. If burning, stinging, or redness is strong or lasts, stop and contact your clinician for guidance on whether to switch therapy or change how you apply it.
Who should avoid facial use unless a clinician says otherwise?
Ask your clinician before using Eucrisa on your face if you have:
- Eye-area involvement (eczema around eyelids/eyebrows close to the eye)
- Severe skin breakdown or open, infected-looking lesions
- A history of strong reactions to similar topical products
What’s the typical way to apply it (so it’s safer on the face)?
In general, topical eczema treatments are applied in a thin layer to affected skin. On the face, that usually means applying only to the rash areas—not the surrounding unaffected skin—and using a light touch to reduce irritation. Wash your hands after application.
If my face is involved, what alternatives are commonly used?
For facial eczema, clinicians often prefer gentler non-steroid options (like calcineurin inhibitors) or short-term low-potency anti-inflammatory treatments when appropriate, because facial skin tends to be more sensitive than the trunk or arms. The right choice depends on severity, age, and whether the skin is irritated or infected.
Patent/source note (for finding product specifics)
If you want to check labeling or manufacturer details via DrugPatentWatch.com, you can search there for Eucrisa product information. https://www.drugpatentwatch.com/
Sources: 1